EBR Systems Advances Leadless CRT with First TLC-AU Study Implant
EBR Systems (ASX: EBR) has achieved a major milestone with the first patient implanted in the Totally Leadless CRT (TLC-AU) study, marking progress toward offering a fully leadless cardiac resynchronisation therapy solution. Conducted at Princess Alexandra Hospital in Brisbane, the procedure combined EBR’s WiSE System with a leadless pacemaker to explore a next-generation approach for newly diagnosed heart failure patients. The feasibility study will enrol up to 40 participants across multiple Australian centres, evaluating the safety, efficacy, and clinical response of this co-implantation strategy over six months. Success in this study could significantly broaden EBR’s market reach, as de novo patients represent roughly 75% of the CRT market. The initiative supports EBR’s aim of positioning WiSE CRT as a first-line, totally leadless alternative as leadless pacing technologies gain momentum in cardiac care.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
x
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to this. Read our Privacy Policy and Terms & Conditions
EBR Systems Advances Leadless CRT with First TLC-AU Study Implant
EBR Systems (ASX: EBR) has achieved a major milestone with the first patient implanted in the Totally Leadless CRT (TLC-AU) study, marking progress toward offering a fully leadless cardiac resynchronisation therapy solution. Conducted at Princess Alexandra Hospital in Brisbane, the procedure combined EBR’s WiSE System with a leadless pacemaker to explore a next-generation approach for newly diagnosed heart failure patients. The feasibility study will enrol up to 40 participants across multiple Australian centres, evaluating the safety, efficacy, and clinical response of this co-implantation strategy over six months. Success in this study could significantly broaden EBR’s market reach, as de novo patients represent roughly 75% of the CRT market. The initiative supports EBR’s aim of positioning WiSE CRT as a first-line, totally leadless alternative as leadless pacing technologies gain momentum in cardiac care.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au